sponsored topics see a problem let us know legal help karyopharm therapeutics inc nasdaqkpti karyopharm therapeutics inc kpti product news news  stocknewscom     follow us stocktwits twitter karyopharm therapeutics inc kpti product news news kpti – doses the first patient in its pivotal phase  boston study jun    pm  by stocknewscom staff product news key facts surrounding this news item kpti had a powr rating of d sell coming into today kpti was  below its day moving average coming into today kpti was  below its day moving average coming into today kpti was  below its day moving average coming into today kpti was  below its day moving average coming into today kpti was  below its day moving average coming into today kpti had returned  yeartodate leading up to today’s news versus a  return from the benchmark sp  during the same period more info about karyopharm therapeutics inc kpti karyopharm therapeutics is a clinicalstage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases the company was founded in  and is based in in newton massachusetts view our full kpti ticker page with ratings news and more kpti at a glance kpti current powr rating™ overall powr rating™ kpti current price   more kpti ratings data and news kpti price reaction the day of this event jun  kpti closing price kpti volume from avgleading up to this eventkpti mo returnnaafter this eventkpti day returnkpti day returnkpti day return kpti price chart more karyopharm therapeutics inc kpti news view all eventdate symbol news detail start price end price change powr rating loading please wait view all kpti news page generated in  seconds kpti stock price  karyopharm therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers xrx  wynn  nrg  incy  has  fl  hal  mat  latest newsall times eastern a updated european stocks march higher as german businesses take ‘euphoric’ tone a investment chief who manages  billion heads to the ‘frontier’ for bigger gains a opinion donald trump may not want to take credit for the stock market just yet a should you buy a starter home or a longterm home a which state’s  plan is right for you a opinion what the solar eclipse on aug  will mean for stocks a softbank pursues multibilliondollar stake in uber a revolution bars terror attacks hurt trading a updated greece returns to international bond markets after year hiatus a german business sentiment hits record high in july to be replaced home investing quotes stocks united states kpti overview compare quotes stock screener earnings calendar sectors nasdaq kpti us nasdaq join td ameritrade find a broker karyopharm therapeutics inc watchlist createkptialert after hours last updated jul    pm edt delayed quote     after hours volume  close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones  stocks to watch aug   at  pm et by harry boxer karyopharm therapeutics started at outperform with  stock price target at rw baird jun   at  pm et by tomi kilgore cfo moves karyopharm education realty trust aug   at  pm et on the wall street journal recent news other news press releases karyopharm therapeutics buy sell or hold karyopharm therapeutics buy sell or hold jun   at  am et on seeking alpha  things in biotech you should learn today june    things in biotech you should learn today june   jun   at  am et on seeking alpha biotech forum daily digest  biotech soars spotlight on novacure biotech forum daily digest  biotech soars spotlight on novacure jun   at  pm et on seeking alpha karyopharms selinexor shows  response rate in dlbcl patients in midstage study karyopharms selinexor shows  response rate in dlbcl patients in midstage study jun   at  pm et on seeking alpha karyopharm therapeutics kpti presents at jefferies  global healthcare conference  slideshow karyopharm therapeutics kpti presents at jefferies  global healthcare conference  slideshow jun   at  pm et on seeking alpha premarket analyst action  healthcare premarket analyst action  healthcare may   at  am et on seeking alpha karyopharm therapeutics kpti ceo dr michael kauffman on q  results  earnings call transcript karyopharm therapeutics kpti ceo dr michael kauffman on q  results  earnings call transcript may   at  am et on seeking alpha q karyopharm therapeutics inc q karyopharm therapeutics inc may   at  pm et on edgar online  edg  q k  things in biotech you should learn today april   apr   at  am et on seeking alpha why karyopharm therapeutics inc stock gained  in march apr   at  am et on motley fool biotech forum daily digest valeants continuing struggles spotlight on glycomimetics apr   at  am et on seeking alpha fda removes partial clinical hold on karyopharms selinexor studies apr   at  pm et on seeking alpha fda lifts partial clinical hold on clinical studies of karyopharms selinexor mar   at  am et on seeking alpha karyopharms selinexor should drive substantial growth mar   at  am et on seeking alpha pharma stock roundup astrazenecas lynparza impresses in study merck drug label expanded mar   at  am et on zackscom karyopharm therapeutics kpti ceo dr michael kauffman on q  results  earnings call transcript mar   at  pm et on seeking alpha karyopharm therapeutics inc  q  results  earnings call slides mar   at  pm et on seeking alpha k karyopharm therapeutics inc mar   at  am et on edgar online  edg  q k aacr  rags to riches to rags again mar   at  pm et on seeking alpha karyopharm follows juno with leukemia drug dud stock topples mar   at  am et on investors business daily karyopharm doses first patient in pivotal phase  boston study evaluating selinexor in patients with relapsedrefractory multiple myeloma karyopharm doses first patient in pivotal phase  boston study evaluating selinexor in patients with relapsedrefractory multiple myeloma jun   at  pm et on globenewswire karyopharm therapeutics to participate in upcoming investor conferences karyopharm therapeutics to participate in upcoming investor conferences may   at  am et on globenewswire karyopharms phase b sadal data evaluating selinexor in diffuse large bcell lymphoma selected for oral presentation at the  european hematology association annual meeting karyopharms phase b sadal data evaluating selinexor in diffuse large bcell lymphoma selected for oral presentation at the  european hematology association annual meeting may   at  am et on globenewswire investor network karyopharm therapeutics inc to host earnings call investor network karyopharm therapeutics inc to host earnings call may   at  am et on accesswire karyopharm to report first quarter  financial results on may   karyopharm to report first quarter  financial results on may   apr   at  am et on globenewswire karyopharm therapeutics announces pricing of public offering of common stock apr   at  am et on globenewswire karyopharm therapeutics announces proposed public offering of common stock apr   at  pm et on globenewswire karyopharm reports interim phase b sadal data at the  american association for cancer research annual meeting apr   at  pm et on globenewswire karyopharm and medidata expand clinical trial partnership apr   at  am et on businesswire  bzx karyopharm announces management change apr   at  pm et on globenewswire karyopharm to present selinexor phase b sadal data at the american association for cancer research annual meeting  mar   at  pm et on globenewswire us fda division of hematology products lifts partial clinical hold on karyopharms selinexor clinical trials mar   at  am et on globenewswire karyopharm to present at the th annual needham healthcare conference mar   at  am et on globenewswire karyopharm reports fourth quarter and full year  financial results and provides selinexor clinical update mar   at  am et on globenewswire karyopharm announces partial clinical hold to pause enrollment in selinexor trials mar   at  pm et on globenewswire karyopharm to report fourth quarter and year end  financial results on march   mar   at  am et on globenewswire karyopharm announces results from interim analysis of phase  sopra study evaluating selinexor in relapsedrefractory acute myeloid leukemia mar   at  pm et on globenewswire karyopharm announces the presentation of new data at the  american association for cancer research annual meeting mar   at  pm et on globenewswire karyopharm to participate in upcoming investor conferences jan   at  am et on globenewswire karyopharm to present at the th annual jp morgan healthcare conference jan   at  am et on globenewswire karyopharm therapeutics inc karyopharm therapeutics inc is a clinicalstage pharmaceutical company which discovers develops and commercializes drugs to treat cancer and other major diseases the company intends to initiate a pivotal randomized phase  study of selinexor in combination with bortezomib velcade and lowdose dexamethasone boston in patients with multiple myeloma karyopharm therapeutics was founded by joseph araujo ronald a depinho pamela a silver giulio draetta michael g kauffman and sharon shacham on december   and is headquartered in newton ma see full profile analyst ratings sell under hold over buy number of ratings  full ratings an expected failure from karyopharms selinexor doesnt change the bull thesis mar   at  am et on benzingacom jefferies upgrades karyopharm to buy as storm data likely to predict sunny skies aug   at  am et on benzingacom  biggest price target changes for tuesday aug   at  am et on benzingacom competitors name chg  market cap immunomedics inc  m exelixis inc  b endocyte inc  m abbott laboratories  b bristolmyers squibb co  b competitor data provided by partner content trending tickers powered by amd  googl  kors  wday  fb  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aeuropean stocks march higher as german businesses take ‘euphoric’ tone ainvestment chief who manages  billion heads to the ‘frontier’ for bigger gains adonald trump may not want to take credit for the stock market just yet ashould you buy a starter home or a longterm home awhich state’s  plan is right for you awhat the solar eclipse on aug  will mean for stocks asoftbank pursues multibilliondollar stake in uber arevolution bars terror attacks hurt trading agreece returns to international bond markets after year hiatus agerman business sentiment hits record high in july achipotle earnings media coverage of the latest illness scare will put earnings targets at risk ahere’s what it looks like when the foreclosure ‘pig’ moves through the housingcrisis ‘python’ agermany ifo business climate index at  in july vs  forecast dj afed to stick to plans for rate hike balancesheet selloff this year aeuro rises to  after german ifo data ais this why united tsa clashed on twitter over comic books on planes amls says no to promotionandrelegation regime — and  billion to boot athe scientifically proven reason you should stop feeling guilty about ordering takeout ahere’s a sign investors are viewing earnings through rosetinted glasses agerman ifo hits record high in july dj loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aeuropean stocks march higher as german businesses take ‘euphoric’ tone ainvestment chief who manages  billion heads to the ‘frontier’ for bigger gains adonald trump may not want to take credit for the stock market just yet ashould you buy a starter home or a longterm home awhich state’s  plan is right for you awhat the solar eclipse on aug  will mean for stocks asoftbank pursues multibilliondollar stake in uber arevolution bars terror attacks hurt trading agreece returns to international bond markets after year hiatus agerman business sentiment hits record high in july achipotle earnings media coverage of the latest illness scare will put earnings targets at risk ahere’s what it looks like when the foreclosure ‘pig’ moves through the housingcrisis ‘python’ agermany ifo business climate index at  in july vs  forecast dj afed to stick to plans for rate hike balancesheet selloff this year aeuro rises to  after german ifo data ais this why united tsa clashed on twitter over comic books on planes amls says no to promotionandrelegation regime — and  billion to boot athe scientifically proven reason you should stop feeling guilty about ordering takeout ahere’s a sign investors are viewing earnings through rosetinted glasses agerman ifo hits record high in july dj loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aeuropean stocks march higher as german businesses take ‘euphoric’ tone ainvestment chief who manages  billion heads to the ‘frontier’ for bigger gains adonald trump may not want to take credit for the stock market just yet ashould you buy a starter home or a longterm home awhich state’s  plan is right for you awhat the solar eclipse on aug  will mean for stocks asoftbank pursues multibilliondollar stake in uber arevolution bars terror attacks hurt trading agreece returns to international bond markets after year hiatus agerman business sentiment hits record high in july achipotle earnings media coverage of the latest illness scare will put earnings targets at risk ahere’s what it looks like when the foreclosure ‘pig’ moves through the housingcrisis ‘python’ agermany ifo business climate index at  in july vs  forecast dj afed to stick to plans for rate hike balancesheet selloff this year aeuro rises to  after german ifo data ais this why united tsa clashed on twitter over comic books on planes amls says no to promotionandrelegation regime — and  billion to boot athe scientifically proven reason you should stop feeling guilty about ordering takeout ahere’s a sign investors are viewing earnings through rosetinted glasses agerman ifo hits record high in july dj loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  kpti stock price  karyopharm therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers xrx  wynn  nrg  incy  has  fl  hal  mat  latest newsall times eastern a updated european stocks march higher as german businesses take ‘euphoric’ tone a investment chief who manages  billion heads to the ‘frontier’ for bigger gains a opinion donald trump may not want to take credit for the stock market just yet a should you buy a starter home or a longterm home a which state’s  plan is right for you a opinion what the solar eclipse on aug  will mean for stocks a softbank pursues multibilliondollar stake in uber a revolution bars terror attacks hurt trading a updated greece returns to international bond markets after year hiatus a german business sentiment hits record high in july to be replaced home investing quotes stocks united states kpti overview compare quotes stock screener earnings calendar sectors nasdaq kpti us nasdaq join td ameritrade find a broker karyopharm therapeutics inc watchlist createkptialert after hours last updated jul    pm edt delayed quote     after hours volume  close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones  stocks to watch aug   at  pm et by harry boxer karyopharm therapeutics started at outperform with  stock price target at rw baird jun   at  pm et by tomi kilgore cfo moves karyopharm education realty trust aug   at  pm et on the wall street journal recent news other news press releases karyopharm therapeutics buy sell or hold karyopharm therapeutics buy sell or hold jun   at  am et on seeking alpha  things in biotech you should learn today june    things in biotech you should learn today june   jun   at  am et on seeking alpha biotech forum daily digest  biotech soars spotlight on novacure biotech forum daily digest  biotech soars spotlight on novacure jun   at  pm et on seeking alpha karyopharms selinexor shows  response rate in dlbcl patients in midstage study karyopharms selinexor shows  response rate in dlbcl patients in midstage study jun   at  pm et on seeking alpha karyopharm therapeutics kpti presents at jefferies  global healthcare conference  slideshow karyopharm therapeutics kpti presents at jefferies  global healthcare conference  slideshow jun   at  pm et on seeking alpha premarket analyst action  healthcare premarket analyst action  healthcare may   at  am et on seeking alpha karyopharm therapeutics kpti ceo dr michael kauffman on q  results  earnings call transcript karyopharm therapeutics kpti ceo dr michael kauffman on q  results  earnings call transcript may   at  am et on seeking alpha q karyopharm therapeutics inc q karyopharm therapeutics inc may   at  pm et on edgar online  edg  q k  things in biotech you should learn today april   apr   at  am et on seeking alpha why karyopharm therapeutics inc stock gained  in march apr   at  am et on motley fool biotech forum daily digest valeants continuing struggles spotlight on glycomimetics apr   at  am et on seeking alpha fda removes partial clinical hold on karyopharms selinexor studies apr   at  pm et on seeking alpha fda lifts partial clinical hold on clinical studies of karyopharms selinexor mar   at  am et on seeking alpha karyopharms selinexor should drive substantial growth mar   at  am et on seeking alpha pharma stock roundup astrazenecas lynparza impresses in study merck drug label expanded mar   at  am et on zackscom karyopharm therapeutics kpti ceo dr michael kauffman on q  results  earnings call transcript mar   at  pm et on seeking alpha karyopharm therapeutics inc  q  results  earnings call slides mar   at  pm et on seeking alpha k karyopharm therapeutics inc mar   at  am et on edgar online  edg  q k aacr  rags to riches to rags again mar   at  pm et on seeking alpha karyopharm follows juno with leukemia drug dud stock topples mar   at  am et on investors business daily karyopharm doses first patient in pivotal phase  boston study evaluating selinexor in patients with relapsedrefractory multiple myeloma karyopharm doses first patient in pivotal phase  boston study evaluating selinexor in patients with relapsedrefractory multiple myeloma jun   at  pm et on globenewswire karyopharm therapeutics to participate in upcoming investor conferences karyopharm therapeutics to participate in upcoming investor conferences may   at  am et on globenewswire karyopharms phase b sadal data evaluating selinexor in diffuse large bcell lymphoma selected for oral presentation at the  european hematology association annual meeting karyopharms phase b sadal data evaluating selinexor in diffuse large bcell lymphoma selected for oral presentation at the  european hematology association annual meeting may   at  am et on globenewswire investor network karyopharm therapeutics inc to host earnings call investor network karyopharm therapeutics inc to host earnings call may   at  am et on accesswire karyopharm to report first quarter  financial results on may   karyopharm to report first quarter  financial results on may   apr   at  am et on globenewswire karyopharm therapeutics announces pricing of public offering of common stock apr   at  am et on globenewswire karyopharm therapeutics announces proposed public offering of common stock apr   at  pm et on globenewswire karyopharm reports interim phase b sadal data at the  american association for cancer research annual meeting apr   at  pm et on globenewswire karyopharm and medidata expand clinical trial partnership apr   at  am et on businesswire  bzx karyopharm announces management change apr   at  pm et on globenewswire karyopharm to present selinexor phase b sadal data at the american association for cancer research annual meeting  mar   at  pm et on globenewswire us fda division of hematology products lifts partial clinical hold on karyopharms selinexor clinical trials mar   at  am et on globenewswire karyopharm to present at the th annual needham healthcare conference mar   at  am et on globenewswire karyopharm reports fourth quarter and full year  financial results and provides selinexor clinical update mar   at  am et on globenewswire karyopharm announces partial clinical hold to pause enrollment in selinexor trials mar   at  pm et on globenewswire karyopharm to report fourth quarter and year end  financial results on march   mar   at  am et on globenewswire karyopharm announces results from interim analysis of phase  sopra study evaluating selinexor in relapsedrefractory acute myeloid leukemia mar   at  pm et on globenewswire karyopharm announces the presentation of new data at the  american association for cancer research annual meeting mar   at  pm et on globenewswire karyopharm to participate in upcoming investor conferences jan   at  am et on globenewswire karyopharm to present at the th annual jp morgan healthcare conference jan   at  am et on globenewswire karyopharm therapeutics inc karyopharm therapeutics inc is a clinicalstage pharmaceutical company which discovers develops and commercializes drugs to treat cancer and other major diseases the company intends to initiate a pivotal randomized phase  study of selinexor in combination with bortezomib velcade and lowdose dexamethasone boston in patients with multiple myeloma karyopharm therapeutics was founded by joseph araujo ronald a depinho pamela a silver giulio draetta michael g kauffman and sharon shacham on december   and is headquartered in newton ma see full profile analyst ratings sell under hold over buy number of ratings  full ratings an expected failure from karyopharms selinexor doesnt change the bull thesis mar   at  am et on benzingacom jefferies upgrades karyopharm to buy as storm data likely to predict sunny skies aug   at  am et on benzingacom  biggest price target changes for tuesday aug   at  am et on benzingacom competitors name chg  market cap immunomedics inc  m exelixis inc  b endocyte inc  m abbott laboratories  b bristolmyers squibb co  b competitor data provided by partner content trending tickers powered by amd  googl  kors  wday  fb  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience contact the board  karyopharm therapeutics careers contact contact the board you can contact karyopharm therapeuticss board of directors to provide comments to report concerns or to ask a question at the following address corporate secretary karyopharm therapeutics  wells ave nd floor newton ma  united states you may submit your concern anonymously or confidentially by postal mail you may also indicate whether you are a shareholder customer supplier or other interested party communications are distributed to the board or to any individual directors as appropriate depending on the facts and circumstances outlined in the communication in that regard the karyopharm therapeutics board of directors has requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded such as product complaintsproduct inquiriesnew product suggestionsresumes and other forms of job inquiriessurveysbusiness solicitations or advertisements in addition material that is unduly hostile threatening illegal or similarly unsuitable will be excluded with the provision that any communication that is filtered out must be made available to any nonmanagement director upon request you may also communicate online with our board of directors as a group please submit your question using the form below  indicates required field name email subject comments listen to audio version type in number submit comment shareholder tools           facebook google linkedin twitter email rss usakaryopharm therapeutics corporate headquarters  wells ave nd floor newton ma    main phone number usa  germanykaryopharm therapeutics sitz der gesellschaft karyopharm europe gmbh franziskabilekweg   münchen germany   tel    –    fax    –    name email message about sine™ technology drug candidates investors publications contact careers   karyopharm therapeutics terms of use privacy policy management team  karyopharm therapeutics careers contact management team michael g kauffmanmd phd chief executive officer sharon shachamphd mba president  chief scientific officer ran frenkelrph chief development operations officer christopher primianojd mba senior vice president operations business development general counsel  secretary brian austadphd vp head of pharmaceutical sciences bill hatfield senior vice president product strategy and market development kevin p malobisky phdms rac senior vice president regulatory affairs quality and pharmacovigilance ronit milstein vp operations john mccartneyphd vp medical writing jatin shahmd vp clinical strategy mike todisco vp finance jas uppalphd vp regulatory affairs michael g kauffmanmd phd chief executive officer dr kauffman cofounded karyopharm with dr sharon shacham in  and has served as our president and chief executive officer since january  as chief medical officer since december  and as a director since  prior to joining karyopharm he was chief medical officer of onyx pharmaceuticals inc a biopharmaceutical company from november  to december  which acquired proteolix inc in november  where he was chief medical officer since november  where he led the development of kyprolis carfilzomib a novel proteasome inhibitor approved in refractory myeloma by the fda in july prior to joining onyx pharmaceuticals dr kauffman was an operating partner at bessemer venture partners from  to  where he led investments in biotechnology companies prior to that he was president and chief executive officer of epix pharmaceuticals inc a biopharmaceutical company that underwent liquidation proceedings in  from  to  and president and chief executive officer of predix pharmaceuticals inc a private biopharmaceutical company focused on g proteincoupled receptors gpcr from  until its merger into epix pharmaceuticals in  where he led the merger of predix pharmaceuticals and epix pharmaceuticals oversaw the discovery and development of four new clinical candidates and led collaboration transactions with amgen and glaxosmithklinefrom march  to september  dr kauffman was vice president clinical at millennium pharmaceuticals inc a biopharmaceutical company where he led the velcade development program from september  to march  dr kauffman held a number of senior positions at millennium predictive medicine inc a biopharmaceutical company and a subsidiary of millennium pharmaceuticals where he led the discovery and development of novel molecular diagnostics for major cancers including melanoma and led transactions with bectondickenson and bristol myers squibbfrom august  to september  dr kauffman held a number of senior positions at biogen idec inc a biopharmaceutical company where he led the clinical development of antidl antibodies in autoimmune and inflammatory diseases and acted as the main medical advisor to the biogen business development group dr kauffman currently serves on the board of directors and compensation committee of verastem inc a public biopharmaceutical companydr kauffman received his ba in biochemistry from amherst college his md and phd from johns hopkins medical school and trained in internal medicine and rheumatology at beth israel now beth israel deaconness medical center and massachusetts general hospitals he is board certified in internal medicine « back to management team sharon shachamphd mba president  chief scientific officer dr shacham founded karyopharm in  and has served as our chief scientific officer and president of research and development since december  as our chief scientific officer and head of research and development from october  to december  and as our president and chief executive officer from october  to january  dr shacham has led our scientific progress since inception prior to joining karyopharm from  to april  she was senior vice president of drug development at epix pharmaceuticals inc which underwent liquidation proceedings in  and director algorithm and software development at predix pharmaceuticals inc which merged into epix pharmaceuticals in  where she led the companys efforts in gpcr modeling computational chemistry lead optimization and development of clinical trials dr shacham received her bsc in chemistry phd and mba from tel aviv university « back to management team ran frenkelrph chief development operations officer mr frenkel was appointed executive vice president worldwide development operations of karyopharm in october  mr frenkel is responsible for managing the subsidiary karyopharm europe gmbh which will provide the corporate structure necessary to support karyopharms expanded clinical and regulatory activities in europe in addition frenkel is responsible for the corporate global development operations across the entire portfolio in this capacity frenkel is managing the clinical departments including clinical operations product leadership quality regulatory affairs medical writing medical  scientific affairs and biology mr frenkel has more than  years of experience in the international biopharmaceutical industry encompassing clinical regulatory business development and commercial operations activities prior to joining karyopharm europe gmbh mr frenkel held a number of senior management roles in europe israel and the united states most recently as managing director emea for clinipace worldwide an international clinical research organization where he had responsibility for the overall management of the organization in europe the middle east and africa prior to joining clinipace worldwide mr frenkel established and managed the israeli office of pfc pharma focus ag which was acquired by clinipace in  and he held the position of managing director at actelion pharmaceuticals with responsibility for all science and business affairs of the company in israel « back to management team christopher primianojd mba senior vice president operations business development general counsel  secretary mr primiano is senior vice president operations business development general counsel  secretary of karyopharm which he joined in march  prior to joining karyopharm mr primiano was a counsel at wilmer cutler pickering hale and dorr llp where he practiced law since october  from august  to august  he served as vice president corporate development general counsel and secretary of glasshouse technologies inc an information technology consulting company where he lead global legal operations and managed asset and subsidiary acquisition and sale activity mr primiano previously worked at gunderson dettmer stough villeneuve franklin  hachigian llp where he practiced law from august  to july  mr primiano received a bachelor of arts in political economy and english from georgetown university a master of business administration from the boston college carroll school of management and a juris doctor from boston college law school « back to management team brian austadphd vp head of pharmaceutical sciences brian austad phd is a senior scientific leader in chemical and pharmaceutical development with  years of pharmaceutical experience specializing in process chemistry with a focus on developing novel medicines for unmet needs he has extensive experience in natural product synthesis and natural product derivatives complex chemistry and optimizing api synthetic routes and manufacturing brian has been a sr advisor in chemical development with rondaxe pharma and was director of process chemistry at infinity pharmaceuticals where he established and built a highly effective process chemistry group responsible for the api development and manufacture of all infinity clinical programs he has previously worked at eisai research institute as a scientist and project leader in process chemistry where he was a core contributor the development and manufacture of halavan® a fully synthetic derivative of the highly complex marine natural product halichondrin b for the treatment of breast cancer brian received his bs degree in chemistry from university of wisconsin  eau claire and his phd in synthetic organic chemistry from the university of wisconsin  madison with prof steven d burke « back to management team bill hatfield senior vice president product strategy and market development bill hatfield joined karyopharm in may  as senior vice president of commercial development bringing with him over  years of experience in oncology marketing commercial strategy and product development in both the pharmaceutical and biotechnology industries in domestic and international markets he has helped develop the commercial oncology teams at several prominent pharmaceutical companies prior to joining karyopharm bill was the vice president new product strategy at sanofi oncology additionally bill held senior level positions in marketing sales and business development at genzyme and at millennium pharmaceuticals where he was instrumental in the us commercial launch of velcade bill graduated magma cum laude from the boston university school of management he holds a bs in business administration with a concentration in marketing « back to management team kevin p malobisky phdms rac senior vice president regulatory affairs quality and pharmacovigilance kevin p malobisky phd ms rac is a regulatory and quality professional with over  years of experience in global leadership management and strategy with a focus in clinical research and development regulatory affairs quality pharmacovigilance and operations in the pharmaceutical and biotechnology arena dr malobisky has extensive experience developing and leading early latephase and commercial regulatory and development strategies with the us food and drug administration and other global health authorities he has also led and participated in numerous regulatory filings across a wide range of therapeutic domains and directed the preparation for an fda advisory committee meeting and numerous risk mitigation and management strategies for development and commercial products prior to joining karyopharm therapeutics dr malobisky was the global head of regulatory and quality at zafgen a biopharmaceutical company focused on metabolic and rare diseases kevin earned his bs degree in microbiology from the pennsylvania state university his ms in regulatory affairs and quality assurance from temple university school of pharmacy and his phd in organization management from capella university school of business and technology kevin is also certified in regulatory affairs us rac from the regulatory affairs professional society « back to management team ronit milstein vp operations « back to management team john mccartneyphd vp medical writing john mccartney has joined karyopharm as vp medical writing to oversee kpt clinical development john has over  years of drug development and project management experience working previously with gliamed epix pharmaceuticals point therapeutics cystic fibrosis foundation therapeutics and curiscreative biomolecules john received his phd in microbiology from duke university and postdoctoral training at the massachusetts institute of technology « back to management team jatin shahmd vp clinical strategy « back to management team mike todisco vp finance michael todisco joined karyopharm in september  as vice president finance mike brings over twentyfive years of accounting and finance experience most recently he was vice president  corporate controller at dicerna pharmaceuticals prior to dicerna mike was vice president  corporate controller at both bg medicine and dusa pharmaceuticals earlier in his career mike was a former audit manager at both ernst  young and kpmg he has his master’s degree in accounting from northeastern and has a ba degree from colgate university where he majored in economics « back to management team jas uppalphd vp regulatory affairs jas uppal phd joined karyopharm in july  as vp regulatory affairs bringing with her over  years of experience across a wide range of product and therapeutic areas including monoclonal antibodies small molecules device combinations and plasma derived therapeutics prior to joining karyopharm she was with biogen idec now biogen for over  years most recently as director global emerging markets head and prior to that as director of development – europe where she provided regulatory leadership in the registration of both biological and small molecule product candidates earlier in her pharmaceutical career jas was manager worldwide regulatory affairs at parexel international and she also held positions at glaxo wellcome plc before joining pharma jas held a number of postdoctoral positions for six years at guys hospital medical school and kings college university of london jas received her phd in biochemistry from kings college university of london « back to management team shareholder tools           facebook google linkedin twitter email rss usakaryopharm therapeutics corporate headquarters  wells ave nd floor newton ma    main phone number usa  germanykaryopharm therapeutics sitz der gesellschaft karyopharm europe gmbh franziskabilekweg   münchen germany   tel    –    fax    –    name email message about sine™ technology drug candidates investors publications contact careers   karyopharm therapeutics terms of use privacy policy us fda division of hematology products lifts partial clinical hold on karyopharm’s selinexor clinical trials nasdaqkpti english français register sign in us fda division of hematology products lifts partial clinical hold on karyopharm’s selinexor clinical trials march    et  source karyopharm therapeutics recruitment resumes across all selinexor trials in hematological malignancies timelines for ongoing and planned studies expected to remain materially unchanged newton mass march   globe newswire  karyopharm therapeutics inc nasdaqkpti a clinicalstage pharmaceutical company today announced that the us food and drug administration fda division of hematology products has lifted the partial clinical hold placed on the clinical trials for selinexor kpt enabling patient enrollment and dosing of new patients in the company’s clinical trials of selinexor in hematological malignancies  the partial clinical hold was not the result of any patient death or any change in the safety profile of selinexor  enrollment may now resume in all selinexor studies in hematologic malignancies including the storm study in refractory multiple myeloma the sadal study in relapsedrefractory diffuse large bcell lymphoma dlbcl and the stomp study of selinexor and backbone therapies in multiple myeloma  in addition investigator sponsored trials in hematologic malignancies with selinexor may resume accruing patients michael g kauffman md phd chief executive officer of karyopharm stated “the karyopharm team worked diligently to update and submit the required documents to the fda which allowed the hematology divison to expeditiously remove the partial clinical hold  we anticipate that the solid tumor divisions will follow suit shortly  patient enrollment is again underway in our hematologic oncology studies  our previously disclosed enrollment rates and timelines for both ongoing and planned trials are not expected to be materially impacted” about selinexor selinexor kpt is a firstinclass oral selective inhibitor of nuclear export  sine™ compound selinexor functions by binding with and inhibiting the nuclear export protein xpo also called crm leading to the accumulation of tumor suppressor proteins in the cell nucleus this reinitiates and amplifies their tumor suppressor function and is believed to lead to the selective induction of apoptosis in cancer cells while largely sparing normal cells to date over  patients have been treated with selinexor and it is currently being evaluated in several mid and laterphase clinical trials across multiple cancer indications including in multiple myeloma in combination with lowdose dexamethasone storm and backbone therapies stomp and in diffuse large bcell lymphoma sadal and liposarcoma seal among others karyopharm plans to initiate a pivotal randomized phase  study of selinexor in combination with bortezomib velcade® and lowdose dexamethasone boston in patients with multiple myeloma in early  additional phase  phase  and phase  studies are ongoing or currently planned including multiple studies in combination with one or more approved therapies in a variety of tumor types to further inform the companys clinical development priorities for selinexor additional clinical trial information for selinexor is available at wwwclinicaltrialsgov about karyopharm therapeutics karyopharm therapeutics inc nasdaqkpti is a clinicalstage pharmaceutical company focused on the discovery and development of novel firstinclass drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases karyopharms sine™ compounds function by binding with and inhibiting the nuclear export protein xpo or crm in addition to singleagent and combination activity against a variety of human cancers sine™ compounds have also shown biological activity in models of neurodegeneration inflammation autoimmune disease certain viruses and woundhealing karyopharm which was founded by dr sharon shacham currently has several investigational programs in clinical or preclinical development for more information please visit wwwkaryopharmcom forwardlooking statements this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  such forwardlooking statements include those regarding the anticipated impact of the partial clinical hold the potential timing for the removal of the partial clinical hold by the solid tumor divisions of the fda therapeutic potential of and potential clinical development plans for karyopharms drug candidates including the timing of initiation of and enrollment in certain trials such statements are subject to numerous important factors risks and uncertainties that may cause actual events or results to differ materially from the companys current expectations for example there can be no guarantee that the fda will release the partial clinical hold in a timely manner or at all any of karyopharms sine™ compounds including selinexor kpt will successfully complete necessary preclinical and clinical development phases or that development of any of karyopharms drug candidates will continue further there can be no guarantee that any positive developments in karyopharms drug candidate portfolio will result in stock price appreciation managements expectations and therefore any forwardlooking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors including the following karyopharms results of clinical trials and preclinical studies including subsequent analysis of existing data and new data received from ongoing and future studies the content and timing of decisions made by the fda and other regulatory authorities investigational review boards at clinical trial sites and publication review bodies including with respect to the need for additional clinical studies karyopharms ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials unplanned cash requirements and expenditures development of drug candidates by karyopharms competitors for diseases in which karyopharm is currently developing its drug candidates and karyopharms ability to obtain maintain and enforce patent and other intellectual property protection for any drug candidates it is developing these and other risks are described under the caption risk factors in karyopharms annual report on form k for the year ended december   which was filed with the securities and exchange commission sec on march   and in other filings that karyopharm may make with the sec in the future any forwardlooking statements contained in this press release speak only as of the date hereof and karyopharm expressly disclaims any obligation to update any forwardlooking statements whether as a result of new information future events or otherwise velcade® is a registered trademark of takeda pharmaceutical company limitedcontacts justin renz   jrenzkaryopharmcom eliza schleifstein   elizaargotpartnerscom related articles other press releases by karyopharm therapeutics karyopharm reports updated phase b sadal data for selinexor in diffuse large bcell lymphoma at the  european hematology association annual meeting june    karyopharm doses first patient in pivotal phase  boston study evaluating selinexor in patients with relapsedrefractory multiple myeloma june    karyopharm therapeutics to participate in upcoming investor conferences may    karyopharm’s phase b sadal data evaluating selinexor in diffuse large bcell lymphoma selected for oral presentation at the  european hematology association annual meeting may    karyopharm reports first quarter  financial results and highlights recent progress may     other news releases in health in the last  days profile karyopharm therapeutics   subscribe via rss  subscribe via atom  javascript newton massachusetts united states contact data contacts justin renz   jrenzkaryopharmcom eliza schleifstein   elizaargotpartnerscom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files karyopharm therapeutics logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft karyopharm therapeutics kpti  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in karyopharm therapeutics inc kpti median target price   upside positive ratings  of  analysts latest  cantor fitzgerald  overweight     view all analyst ratings for kpti » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising karyopharm therapeutics inc  health   web results aol search skip over navigation search the web web images images kpti stock predictions  flashratingscom ad · flashratingscom all current analyst ratings and price targets for kpti about us flashratings principles analyst ranking privacy searches related tokaryopharm therapeutics inc karyopharm therapeutics inc bankruptcy karyopharm therapeutics newton ma karyopharm stock jim cramer karyopharm therapeutics karyopharm pharmaceuticals kpti message board selinexor karyopharm karo pharma web results home  karyopharm therapeutics httpswwwkaryopharmcom karyopharm therapeutics inc is a clinicalstage pharmaceutical company focused on discovery and development of novel firstinclass drugs directed against nuclear  about careers investor relations events  presentations press releases kpti stock price  karyopharm therapeutics inc stock  wwwmarketwatchcominvestingstockkpti karyopharm therapeutics inc stock price stock quotes and financial overviews from marketwatch why karyopharm therapeutics inc stock gained  in  httpswwwfoolcominvestingwhykaryopharm why karyopharm therapeutics inc stock gained  in march it was an exciting month of ups and downs for the biotech and its bloodcancer candidate karyopharm therapeutics inc  kpti  stock price today  httpswwwzackscomampstockquotekpti view karyopharm therapeutics inc kpti investment  stock information get the latest karyopharm therapeutics inc kpti detailed stock quotes stock data realtime  kpti key statistics  karyopharm therapeutics inc  wwwmarketwatchcominvestingstockkptiprofile updated key statistics for karyopharm therapeutics inc  including kpti margins pe ratio valuation profitability company description and other stock  kpti stock quote  karyopharm therapeutics inc common  wwwnasdaqcomsymbolkpti stock quote for karyopharm therapeutics inc common stock kpti  get realtime last sale and extended hours stock prices company news charts and companyspecific  karyopharm therapeutics inc nasdaqkpti quotes  news  wwwgooglecomfinancecid get detailed financial information on karyopharm therapeutics inc nasdaqkpti including realtime stock quotes historical charts  financial news all for free financials  filings  karyopharm therapeutics investorskaryopharmcomfinancialscfm the investor relations website contains information about karyopharm therapeutics business for stockholders potential investors and financial analysts karyopharm therapeutics inc kpti after hours trading  wwwnasdaqcomsymbolkptiafterhours karyopharm therapeutics inc kpti after hours trading  view free after hours stock trades at nasdaqcom kpti stock predictions  flashratingscom ad · flashratingscom all current analyst ratings and price targets for kpti about us flashratings principles analyst ranking privacy searches related tokaryopharm therapeutics inc karyopharm therapeutics inc bankruptcy karyopharm therapeutics newton ma karyopharm stock jim cramer karyopharm therapeutics karyopharm pharmaceuticals kpti message board selinexor karyopharm karo pharma next answers cytori therapeutics cytori therapeutics inc of the united states is a pharmaceutical company based in san diego the company develops and manufactures medical devices more acorda therapeutics products products on the market zanaflex ampyra qutenza products under development cvt plumiaz discontinued may th  references external more corcept therapeutics corcept therapeutics inc is a pharmaceutical company developing products that regulate the effects of cortisol the stress hormone and deal with more search the web  aol inc all rights reservedprivacy   terms of use   preferences   contact us   powered by bing™ wowcom  part of the aol search network investor relations  karyopharm therapeutics careers contact investor relations corporate profile karyopharm therapeutics inc is a clinicalstage pharmaceutical company focused on the discovery and development of novel firstinclass drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases karyopharm’s sine™ compounds function by binding with and inhibiting the nuclear export protein xpo or crm in addition to singleagent and combination activity against a variety of human cancers sine™ compounds have also shown biological activity in models of neurodegeneration inflammation autoimmune disease certain viruses and woundhealing karyopharm was founded by dr sharon shacham in december  and is headquartered in newton massachusetts nasdaq kpti    day high na day low  na volume    na  pm et on jul   delayed at least  minutes  mo  mo  yr corporate presentation corporate presentation july  download pdf press releases jun   karyopharm reports updated phase b sadal data for selinexor in diffuse large bcell lymphoma at the  european hematology association annual meeting jun   karyopharm doses first patient in pivotal phase  boston study evaluating selinexor in patients with relapsedrefractory multiple myeloma view all press releases » events  presentations jun   at  am et jefferies  global healthcare conference listen to webcast may   at  am et karyopharm therapeutics q  earnings call listen to webcast view all events  presentations » shareholder tools           facebook google linkedin twitter email rss usakaryopharm therapeutics corporate headquarters  wells ave nd floor newton ma    main phone number usa  germanykaryopharm therapeutics sitz der gesellschaft karyopharm europe gmbh franziskabilekweg   münchen germany   tel    –    fax    –    name email message about sine™ technology drug candidates investors publications contact careers   karyopharm therapeutics terms of use privacy policy bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one